

Remarks

In response to the Restriction Requirement, dated September 20, 2007, Applicant hereby elects without traverse Group III (claims 16 to 19 and 23 to 26) drawn to methods of inhibiting viral infection with isolated viral proteins.

Applicants have amended the specification to reflect proper priority information and to correct typographical errors. Without prejudice or disclaimer, Applicants have canceled claims 1 to 15, 20 to 22, and 27 to 30. Applicants have amended claims 16 to 19, 23 to 26. Applicants have also added new claims 31 to 46. Exemplary written support for the new claims can be found in the specification as outlined in the table below.

Claim	Exemplary Support
31 to 35	Claim 23
36	Page 19, lines 16 to 18
37	Claim 11
38	Page 17, line 25 to page 18, line 20
39	Page 6, line 22
40	Claim 24
41	Claim 25
42	Claim 26
43 to 46	Page 10, line 21 to page 11, line 9

No new matter has been added by this amendment. Applicant submits that the pending claims are all directed to the elected invention.

Conclusion


It is respectfully submitted that all claims are now in condition for allowance, early notice of which would be appreciated. Should the Examiner disagree, Applicant respectfully requests a telephonic or in-person interview with the undersigned attorney to discuss any remaining issues and to expedite the eventual allowance of the claims.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any necessary fees during the entire pendency of this application including fees due

under 37 C.F.R. 1.16 and 1.17, which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310.

Dated: **January 22, 2008**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801